TCGA-D6-6824-01A-11R-1915-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_UP+0.400
- UV_RESPONSE_DN+0.390
- PROTEIN_SECRETION+0.380
- ANGIOGENESIS+0.340
- ANDROGEN_RESPONSE+0.320
- COMPLEMENT+0.300
- INFLAMMATORY_RESPONSE+0.300
- ALLOGRAFT_REJECTION+0.290
- HEDGEHOG_SIGNALING+0.280
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.270
Top 10 suppressed
- MYC_TARGETS_V2-0.680
- E2F_TARGETS-0.640
- MYC_TARGETS_V1-0.630
- G2M_CHECKPOINT-0.490
- DNA_REPAIR-0.470
- OXIDATIVE_PHOSPHORYLATION-0.450
- MTORC1_SIGNALING-0.410
- P53_PATHWAY-0.330
- UV_RESPONSE_UP-0.310
- CHOLESTEROL_HOMEOSTASIS-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-99-7458-01A-11R-2039-07 | — | cohortA1 | 0.913 |
| 2 | TCGA-CR-7391-01A-11R-2016-07 | — | — | 0.866 |
| 3 | SRR2016976 | — | — | 0.858 |
| 4 | TCGA-55-7724-01A-11R-2170-07 | — | cohortMD2 | 0.858 |
| 5 | MNG47 | — | — | 0.856 |
| 6 | TCGA-55-7907-01A-11R-2170-07 | — | cohortA1 | 0.856 |
| 7 | TCGA-AC-A2FF-01A-11R-A17B-07 | — | A | 0.855 |
| 8 | TCGA-55-7816-01A-11R-2170-07 | — | cohortMD2 | 0.850 |
| 9 | TCGA-CR-7392-01A-11R-2016-07 | — | — | 0.847 |
| 10 | TCGA-BH-A1EU-01A-11R-A137-07 | — | A | 0.846 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_UP | 0.400 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.390 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.380 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.340 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.320 | Inavolisib | — uncovered |
| COMPLEMENT | 0.300 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.290 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.280 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.270 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.260 | Inavolisib | — uncovered |
| COAGULATION | 0.250 | Binimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.250 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.240 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.200 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.150 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.140 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.080 | Temsirolimus | — uncovered |
| XENOBIOTIC_METABOLISM | 0.070 | Inavolisib | — uncovered |